Introduction
Dengue and chikungunya are arboviruses transmitted by the daybiting mosquitoes Aedes aegypti and Aedes albopictus [1, 2] . The vectors of these viruses currently circulate in large parts of the world, rendering 40% of the world population susceptible to these diseases [3] . Chikungunya led to devastating epidemics when introduced in the Americas at the end of 2013 [4, 5] . In the same regions, dengue is endemic with an increasing spread to previously unaffected areas [6] . Concomitant dengue and chikungunya infection have been reported in several regions worldwide, in particular in Africa and Asia [7] . However, considering the high transmission rates of both diseases, co-infections of dengue and chikungunya are surprisingly little reported [8, 9] . Saint Martin, a Caribbean island where the first locally transmitted chikungunya cases were reported in the Caribbean and America, also described the first co-infections of dengue and chikungunya in these regions [10] .
Curaçao became affected by the epidemic of chikungunya up from mid-2014. The outbreak rapidly spread and at the end of the epidemic in January 2015, an estimated 50,000 to 75,000 inhabitants were infected [IG, unpublished] . This epidemic took place in a naïve population for chikungunya against the backdrop of well-established dengue transmission, with outbreaks during the rainy season [11] . All four dengue virus serotypes co-circulate in Curaçao [11] .
Dengue and chikungunya lead to similar acute clinical presentations, typically starting with an abrupt onset of fever, which may be accompanied by a range of symptoms such as rash, headache, myalgia and arthralgia [1, 2] . Disease may evolve into severe conditions and cause death in the case of dengue [2] , while chikungunya is recognized for its debilitating long-lasting musculoskeletal symptoms, which may persist for years [12] [13] [14] . The clinical spectrum of dengue and chikungunya co-infections is not well described, and focuses on acute disease manifestations or complications. These studies do not show substantial differences in disease presentation [15] [16] [17] ; however, complicated disease was described in co-infected patients [17] .
To assess the knowledge gap concerning infections of chikungunya and dengue, this study investigated the impact of a preceding dengue infection on acute and chronic chikungunya disease presentation and analysed predicting factors for chronic sequelae.
Study methods
During June and July 2015, a retrospective cohort study was set up including laboratory confirmed (by serology (ELISA), reverse transcription polymerase chain reaction (RT-PCR) or indirect fluorescent antibody (IFA)) chikungunya cases infected during the 2014 epidemic in Curaçao. Participant recruitment procedures and study site were described elsewhere [18] . Briefly, adult participants' data was provided by general practitioners, working in 14 practices across Curaçao. Assessment of long-term chikungunya sequelae was performed in the homes of participants as part of a cross-sectional survey study.
Study objectives
This study has different objectives. These objectives have distinct inclusion criteria (see Fig. 1 ), and therefore the sample size differs per objective. The objectives with their inclusion criteria are presented in Fig. 1 and are as follows: -Objective 1: To analyse acute clinical presentation of preceding dengue infection and chikungunya-only disease. Inclusion criteria: subjects with clinical data of acute disease presentation and available dengue serology (n = 94); -Objective 2: To analyse predicting factors of chronic disease outcomes: (a)severe disease development and (b) disease persistence > 90 days. Inclusion criteria: subjects with clinical data of acute disease presentation (n = 159); -Objective 3: To analyse chronic clinical presentation of preceding dengue infection and chikungunya-only disease. Inclusion criteria: subjects with available dengue serology (n = 162).
Data collection
Individuals were surveyed using a structured questionnaire assessing socioeconomic variables, co-morbidities, chronic chikungunya sequelae and chikungunya disease status; the latter being assessed using the formerly described Curaçao Long-Term Chikungunya Sequelae (CLTCS) score, where individuals with chronic chikungunya sequelae were classified as 'recovered', 'mildly affected' or 'highly affected' [18] . Trained, experienced local interviewers applied the questionnaire, which was piloted and adapted in Dutch, and translated to Papiamentu, Spanish and English [18] .
The Ministry of Health of Curaçao is responsible for disease surveillance. During outbreaks, physicians are requested to report any suspected case to the Ministry of Health. Data from acute disease presentation was acquired via general practitioners, who assessed suspected chikungunya cases using a standardized form for chikungunya surveillance (Table 1 ) and referred them for dengue serology. Enzymelinked immunosorbent assay (ELISA; DxSelect™, Focus Diagnostics) of acute samples and, if available, convalescent samples was performed by the Analytical Diagnostic Centre (ADC N·V.) in Curaçao according to the manufacturer's protocol, to detect dengue-specific IgM and IgG.
Classification of dengue serology
Classification of serologic outcomes was determined as presented in Table 2 .
We expected that a positive IgM for dengue and laboratory confirmed dengue could influence clinical manifestations. Therefore, patients diagnosed with an acute or presumptive/recent dengue infection were merged into one group, to which we hereinafter refer as 'preceding dengue'. On the other hand, the 'past dengue' and the 'negative cases' were merged and are hereinafter referred to as chikungunya-only (i.e. no preceding dengue infection).
Data analysis
Data analysis procedures were described elsewhere [18] . Briefly, odds ratios of acute and chronic symptoms were calculated and adjusted for confounding factors using a binary logistic regression. Possible confounding of acute or chronic clinical presentation between individuals with chikungunya-only and a preceding dengue disease Additional analyses: these analyses are presented in Appendix A, and were additionally performed since the sample size in the main manuscript was limited. The additional analyses also include the sample which was not tested for dengue. Therefore, these results should be interpret with caution. episode due to age, sex and co-morbidity was explored ( Table 3) . Variables associated with a preceding dengue infection at a p ≤ 0.200 level were considered as confounding variables, namely concomitant diabetes mellitus and cardiovascular disease (for acute and chronic clinical presentation) and age (for chronic clinical presentation) ( Table 3 ). The same procedures were performed in the additional analyses presented in Appendix A.
A multivariate binary logistic regression was performed to investigate predicting factors of chronic chikungunya (sequelae lasting longer than 90 days), and 'highly severe' chronic chikungunya disease outcomes, based on the CLTCS-score. The 'highly severe' disease status was chosen, because it reflects a chronic chikungunya disease status associated with severely reduced quality of life [18] . The multivariate analyses included all clinical and general characteristic variables which were associated with the dependent variables at a significance level of p < 0.20. To obtain more insights and power, additional analyses of acute and chronic disease presentation were performed in Appendix A. These analyses followed the same procedures as the main manuscript, but included the participants without available dengue serology and should therefore be interpreted with caution.
Ethics statement
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Results
In June and July 2015, 304 laboratory-confirmed chikungunya cases were included in a cohort study ( Fig. 1 ). The socio-economic characteristics of the individuals were described previously [18] . Of the 304 individuals, 299 consented to participate in the present study of which 162 were tested for dengue exposure. Fifty-seven participants were defined as having had a preceding dengue infection. Of those, 11 had a laboratory confirmed dengue and 46 a 'presumptive/recent 
Acute clinical presentation
To understand if the acute disease presentation of chikungunya was influenced by a preceding dengue infection, symptoms assessed by general practitioners were compared and adjusted for concomitant diabetes mellitus and concomitant cardiovascular disease (Table 1) . Cough was more frequently reported in individuals with only chikungunya (chikungunya: 18.1% [n = 16] vs. preceding dengue infection: 5.7% [n = 2]; adjusted p-value = 0.017). No other symptoms of acute presentation were associated with having a chikungunya-only or preceding dengue, neither in the additional analyses in Tables A1, A2.
Predicting factors of disease outcomes
Clinical characteristics of long-term chikungunya sequelae were assessed between 92 and 419 days after onset of acute disease. Uni-and multivariate analyses were performed to identify predicting factors of two disease outcomes: 1) chikungunya disease persistence > 90 days, and 2) development of a 'highly affected' CLTCS-disease status. In 66.5% (n = 105) of the cases, chikungunya disease persisted > 90 days and 25.8% (n = 41) were 'highly affected' at time of interview. Timebetween-interview and disease onset was assessed as potential confounder, but showed a similar distribution for the 'recovered and mildly affected' and 'highly affected' individuals (Mean = 267 days, SD = 75 days vs. Mean = 258 days, SD = 57 days; T-test: p = 0.431). In the univariate analysis, disease outcomes were compared with socio-economic characteristics, co-morbidity and clinical presentation at acute disease presentation (Table 4 ). Variables associated at a level of p ≤ 0.20 were included in the multivariate analysis. The final models of the multivariate analysis are presented in Table 5 . An age between 41 and 60 (OR = 3.07; p = 0.009) (baseline category: age of 18-40) and concomitant cardiovascular disease (OR = 4.08; p = 0.010) were independent predictors of chikungunya disease longer than 90 days. 'Highly affected' disease status was predicted by female sex (OR = 3.17; p = 0.034), concomitant joint disease (OR = 2.91; p = 0.031) and preceding dengue (OR = 4.17; p = 0.004) (although the baseline category 'no dengue serology' was used).
Long-term sequelae
Clinical chronic chikungunya presentation of the 162 individuals was compared between those with and without a preceding dengue infection, adjusted for age, concomitant diabetes mellitus and concomitant cardiovascular disease. Participants with a preceding dengue infection at disease onset reported higher proportions of most chronic symptoms ( Table 6 , Fig. 2 , Table A3 ), but no significant associations were found. Chronic joint pain in lower extremities was associated with a preceding dengue infection (OR = 1.86; p = 0.044) in the additional analyses in Table A3 .
Discussion
In June and July 2015, a retrospective cohort study was performed to investigate the influence of a preceding dengue infection on chikungunya disease development. Chikungunya and a preceding dengue infection covered 35.2% of the subjects serologically tested for both diseases, which is amongst the highest incidences reported to date. As reviewed by Furuya-Kanamori and colleagues, the vast majority of studies report incidences of 'co-infections' up to 10% of the study population [19] . Most of these studies assessing 'co-infection' relied, like the present study, (partly) on ELISA-IgM assessment when estimating concomitant prevalence of chikungunya and dengue. It is important to note here that ELISA-IgM assessment alone is not specific enough to define co-infection.
Very few studies describe acute clinical disease presentation of chikungunya and a preceding dengue infection [8, 20] . Even fewer of these included chikungunya-only infections and show, like the present study, no major differences with preceding or co-infected subjects in acute disease presentation [15] [16] [17] but reported complicated disease manifestations [17] . It is notable that patients with chikungunya and a preceding dengue infection were assessed as having more myalgia (OR = 3.0) and arthritis (OR = 1.6). This contradicts the findings of the study by Taraphdar et al. where patients with a preceding dengue infection and chikungunya presented with milder musculoskeletal manifestation than the chikungunya-only infected population [15] . Acute chikungunya (without preceding dengue) presented more often with cough when compared to chikungunya with recent dengue (OR = 7.1; p = 0.017). Cough is a relatively infrequent symptom at acute disease and might differentiate between a chikungunya-only infection and a chikungunya with recent dengue, although we could not find a pathophysiological explanation for this finding. Compared to other studies on acute chikungunya disease presentation, this study reported similar proportions of fever [21] [22] [23] [24] [25] , arthralgia [21] [22] [23] [24] 26] and rash [22] [23] [24] [25] while myalgia [21, 23, 24, 26] and headache [21, [23] [24] [25] were reported in higher proportions. These results indicate that differentiating between chikungunya-only infections and infections of chikungunya with recent dengue at acute presentation remains difficult and depends on laboratory assessment. This is the first study describing that chikungunya with preceding dengue at acute disease presentation is a predicting factor (OR = 4.1) for severe chronic disease development. This independent association was most prominent when compared to the subjects without available dengue serology, but not significant (OR = 1.9; p = 0.159) when compared to the chikungunya-only subjects. It is likely that the group without available dengue serology consisted mainly of 'past dengue' or 'dengue negative' subjects, whilst a lower proportion would have had dengue before. Therefore, we conclude that the latter bias may only have led to an underestimation of differences between the two groups.
The independent association of dengue infection preceding chikungunya and developing a 'highly affected' chronic disease status was reflected in the chronic clinical presentation, where the vast majority of chronic symptoms was reported in higher proportions in this group (i.e. arthralgia, myalgia, fatigue, insomnia and neuropsychological symptoms). In particular the higher proportions of chronic joint pain in the lower extremities, which have previously been associated with the 'highly affected' disease status [18] , may be responsible for this association. The outcomes of the analyses on predicting factors and chronic disease manifestations might suggest that a preceding dengue infection aggravates chronic (chikungunya) sequelae. However, the results of this study alone are not sufficient enough to draw a strong conclusion about this. Several studies that focused on predicting chikungunya disease persistence have identified age [27] [28] [29] , sex [29] , co-morbidity [27, 30] , or acute disease presentation [27] [28] [29] [30] as determinants, but did not assess preceding/co-infection of dengue. This study also identified age, co-morbidity (joint disease and cardiovascular disease) and female sex as predicting factors for longer or worse disease outcome. These predicting factors may aid in assessing the need to follow up chikungunya patients. Furthermore, they may guide further fundamental research on the poorly understood pathophysiology of chikungunya and dengue co-infections.
In this manuscript, we assessed the influence of (preceding) dengue on chikungunya sequelae. It is important to note that diagnosis of chikungunya was based on laboratory testing and clinical evaluation by a physician. When both IgM serology of dengue and chikungunya were positive following acute disease, it was hard to say which of the two diseases caused the acute disease manifestations in this case, and in which order these diseases afflicted the patient. However, it is likely that chikungunya played the most significant role in the acute phase, considering the opinion of the physician and that asymptomatic disease is less common in chikungunya than in dengue. Therefore, we choose to refer to these cases as 'chikungunya with preceding dengue'.
An important limitation of this study was the small sample size of participants tested for dengue (162/299), with consequent implications for the power and representativeness of the study. Parallel analyses were done on acute and long-term clinical presentation to obtain higher power in the analyses (presented in Appendix A). The results of Table  A1 -A3 should be interpreted with caution, because it is likely that some of the subjects without dengue serology had a preceding dengue infection. Since little is known about clinical presentation of chikungunya with preceding dengue infection in other contexts than in Curaçao, generalization of this study should be limited. Due to the recruiting procedures, a referral bias can be present in this study. Also, in some cases laboratorial assessment relied on serology of one sample, which may have lowered the probability to determine a dengue infection. Further, ELISA-based serological assays of dengue are less reliable than RT-PCR or viral isolation and might cross-react with (vaccines of) various flaviviruses (e.g. Japanese encephalitis, yellow fever). However, based on the epidemiological situation of Curaçao at the time of the study, we have no reasons to assume that cross-reaction has significantly influenced the results of this study.
Chikungunya sequelae were prominent in the population with a preceding dengue infection (which included patients with an acute dengue infection) and chikungunya disease, suggesting survival of chikungunya virus during concurrent dengue infection. Though severe dengue disease manifestations were not assessed in this study, they have been described during co-infection with chikungunya [17] . Under which circumstances these sequelae present might be understood through further research regarding (pathophysiology of) chikungunya and (preceding) dengue (co-)infections. For example, clinical manifestations might be influenced by order of infection or viral load of the two viruses.
The high incidence of dengue infection preceding chikungunya disease and the presence of concurrent infection advocate for a critical clinical assessment of patients presenting with fever-like diseases in a chikungunya epidemic against the backdrop of a high dengue endemicity. As co-infections are not easily distinguishable from chikungunya-only infections based on acute clinical presentation, concomitant dengue might be missed in diagnosis. In the latter case, dengue disease can still develop into severe disease conditions. Hence, when a patient presents with acute fever in an area where dengue and chikungunya circulate, it is important to perform laboratory diagnosis to confirm presence of these viruses. Additionally, this will provide valuable information for further chronic disease development, as patients with preceding dengue infection and chikungunya disease might have higher chances to develop a severe long-term disease associated with decreased long-term quality of life [18] .
This study described several risk factors for prolonged and severe long-term chikungunya sequelae. Furthermore, it presents clinical presentation of preceding dengue infection with chikungunya and suggest that there might be a link between preceding dengue infection and aggravated chronic sequelae. However, considering the limitations of this study, this possible link should be further investigated before a conclusion can be drawn. The possible consequences, but little knowledge on the consequences of the ongoing spread of these viruses, raise an urgent call to investigate the clinical presentation and pathophysiology of co-circulating (i.e. chikungunya, dengue and Zika) arboviruses.
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The analysis performed in this document includes also the subjects who were not serologically assessed for dengue. This group was included in the 'Chikungunya infection'-group, and concerned 137 individuals (of which 65 had data available on acute disease presentation) (See flowchart in Fig. 1 ). The remaining individuals were classified as was described in the main manuscript. At interpretation of these data, this limitation should be taken into account. 
